<?xml version="1.0" encoding="UTF-8" ?>
<Event Id="13560233" lastUpdate="Thursday, December 17, 2020 at 2:48:55am GMT" eventTypeId="5" eventTypeName="Corporate Conference Call/Presentation">
  <EventStory Id="13560233.F" expirationDate="Wednesday, December 16, 2020 at 3:00:00pm GMT" action="publish" storyType="transcript" version="Final">
    <Headline><![CDATA[Edited Transcript of NOVOb.CO conference call or presentation 16-Dec-20 3:00pm GMT]]></Headline>
    <Body><![CDATA[Novo Nordisk A/S to Announce the Decision to Enter the Phase 3 Development in Alzheimer's Disease with Oral Semaglutide Call

2880 Bagsvaerd, Dec 17, 2020 (Thomson StreetEvents) -- Edited Transcript of Novo Nordisk A/S conference call or presentation Wednesday, December 16, 2020 at 3:00:00pm GMT

TEXT version of Transcript

]]></Body>
  </EventStory>
  <eventTitle><![CDATA[Novo Nordisk A/S to Announce the Decision to Enter the Phase 3 Development in Alzheimer's Disease with Oral Semaglutide Call]]></eventTitle>
  <city>2880 Bagsvaerd,</city>
  <companyName>Novo Nordisk A/S</companyName>
  <companyTicker>NOVOb.CO</companyTicker>
  <startDate>16-Dec-20 3:00pm GMT</startDate>
</Event>